Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Vanguard Dividend Appreciation Index Fund ETF trades at $238.01. The key difference: Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | VIG | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | — |
52-Week High | $1.82 | $239.03 |
52-Week Low | $0.53 | $204.09 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
VIG trades at $238.48, down 0.15% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF shows strong institutional support and consistent dividend growth, with a recent $1.00 dividend declared for June 2026. Current price sits near key support at $238, with resistance at $239.
The outlook remains positive given VIG's focus on dividend growth stocks and low expense ratio. Key risks include market volatility and interest rate sensitivity, but the ETF's quality holdings provide defensive characteristics during market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
